- Home
- ALLE vs PTGX Comparison
ALLE vs PTGX Comparison
Compare ALLE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLE | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 9.5B |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ALLE | PTGX |
|---|---|---|
| Price | $165.64 | $149.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $167.13 | $108.23 |
| AVG Volume (30 Days) | ★ 1.3M | 523.9K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 3.74 | 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $8.47 | $874.25 |
| Revenue Next Year | $4.58 | N/A |
| P/E Ratio | ★ $45.17 | $62.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $125.00 | $53.49 |
| 52 Week High | $183.11 | $148.00 |
Technical Indicators
Market Signals| Indicator | ALLE | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 70.70 | 67.42 |
| Support Level | $162.88 | $127.98 |
| Resistance Level | $167.46 | N/A |
| Average True Range (ATR) | 4.40 | 4.98 |
| MACD | 1.16 | 0.48 |
| Stochastic Oscillator | 84.14 | 89.70 |
Price Performance
Historical ComparisonAbout ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.